Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Drug Profile

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; Stiolto; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva Respimat

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 17 May 2019 Updated efficacy data from the phase III DYNAGITO trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 11 Oct 2018 The US FDA approves sNDA for inclusion of chronic bronchitis and emphysema in treatment of patients with Chronic obstructive pulmonary disease
  • 18 Jul 2018 Registered for Chronic obstructive pulmonary disease in China (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top